Literature DB >> 31688225

Cataract surgery and intraocular pressure in glaucoma.

Cara E Capitena Young1, Leonard K Seibold, Malik Y Kahook.   

Abstract

PURPOSE OF REVIEW: To review the current literature on the relationship between cataract extraction and intraocular pressure (IOP). RECENT
FINDINGS: Cataract extraction can be an effective IOP lowering treatment for open and closed angle glaucoma as well as ocular hypertension. In comparative trials studying novel micro-invasive glaucoma surgeries in open angle glaucoma, the control group undergoing cataract extraction alone routinely achieved significant reductions in IOP and medication use postoperatively. Data from the Effectiveness in Angle Closure Glaucoma of Lens Extraction (EAGLE) trials have demonstrated that lens extraction is more effective at lowering IOP than peripheral iridotomy in patients with angle closure and should be considered as first line therapy. Additionally, patients in the ocular hypertension treatment study who underwent cataract extraction over the course of follow-up demonstrated significant IOP lowering sustained over 3 years.
SUMMARY: Cataract extraction is an effective method to lower IOP in patients with glaucoma. Pressure lowering is more significant in eyes with narrow angles and those with higher baseline IOP levels. In eyes with angle closure, phacoemulsification alone can lower IOP, but when combined with GSL it may be even more effective. Recent large multicenter randomized trials have further elucidated the benefit of standalone cataract extraction to treat mild to moderate primary open angle glaucoma. Prospective and longitudinal studies that systematically investigate the variables that may influence degree and duration of IOP lowering post cataract extraction are lacking.

Entities:  

Mesh:

Year:  2020        PMID: 31688225     DOI: 10.1097/ICU.0000000000000623

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  7 in total

1.  Gonioscopy-assisted transluminal trabeculotomy in primary angle-closure glaucoma.

Authors:  Eamon Sharkawi; Paul H Artes; Daniel Josef Lindegger; Maria Laura Dari; Mohamad El Wardani; Jérôme Pasquier; Adriano Guarnieri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-22       Impact factor: 3.117

2.  Factors associated with vision loss in Black or Hispanic patients 1 year after standalone or combined Ahmed glaucoma valve surgery.

Authors:  Nicholas E Tan; Shannon X Chen; Nathan M Radcliffe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-26       Impact factor: 3.535

3.  Outcomes of chronic angle-closure glaucoma treated by phacoemulsification and endocyclophotocoagulation with or without endoscopically goniosynechialysis.

Authors:  Xing Wu; Ying Wang; Xi Liu; Zhao-Hui Li; Li-Qin Deng; Dai-Shi Chen; Da-Jiang Wang
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

4.  Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study.

Authors:  Haochen Xu; Marwa T Thomas; Dayeong Lee; Matthew T Hirabayashi; Jella A An
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-11       Impact factor: 3.535

5.  Long-term outcomes of prediction error after combined phacoemulsification and trabeculectomy in glaucoma patients.

Authors:  Yeon Soo Kang; Mi Sun Sung; Hwan Heo; Yong Sok Ji; Sang Woo Park
Journal:  BMC Ophthalmol       Date:  2021-01-26       Impact factor: 2.209

6.  Time trends, associations and prevalence of blindness and vision loss due to glaucoma: an analysis of observational data from the Global Burden of Disease Study 2017.

Authors:  Yi Sun; Aiming Chen; Minjie Zou; Yichi Zhang; Ling Jin; Yi Li; Danying Zheng; Guangming Jin; Nathan Congdon
Journal:  BMJ Open       Date:  2022-01-06       Impact factor: 2.692

7.  Reasons for choice of glaucoma surgery in eyes not treated with anti-glaucoma medications.

Authors:  Kazunobu Sugihara; Hiroki Fukuda; Tetsuro Omura; Masaki Tanito
Journal:  BMC Ophthalmol       Date:  2022-03-30       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.